Debt-ridden Wockhardt Ltd has divested its German business Esparma to Mova GmbH, a subsidiary of Lindopharm GmbH, Germany, for an undisclosed amount. The development comes as the Mumbai-based drug maker sets about the...
Tanu Healthcare Shareholders approves Scheme of Amalgamation
Tanu Healthcare Ltd has informed BSE that as per the direction of the Honorable High Court, Mumbai, the Company has convened the EGM of Shareholder on June 13, 2009 in the matter of the Scheme of Amalgamation of Blue...
Jubilant Organosys may sell polymer unit to cut debt
Debt-ridden contract manufacturing specialist Jubilant Organosys today said it was evaluating its performance polymers division, a non-core business of the pharma major, for possible divestment. Jubilant had a net debt...
Jubilant mulls sale of performance polymer biz
Pharmaceutical major Jubilant Organosys Ltd on Tuesday said it is looking at selling off its non-core business of industrial performance polymers. “The company is strategically focusing on pharmaceuticals and life...
Matrix and Aspen complete divestment of Joint Ventures
Matrix Laboratories Ltd has informed BSE regarding a Press Release dated June 01, 2009 titled "Matrix and Aspen complete divestment of Joint Ventures"
Take Solutions deal with Korean co
Chennai-based Take Solutions has struck a deal with IL-Yang Pharmaceutical Company of South Korea, under which Take will provide ‘investigational new drug submission services’ to the pharma company. The...
Taro acquisition may cost Sun Pharma Rs 1,000 cr
Indian drug firm Sun Pharma may have to shell out up to Rs 1,000 crore this fiscal for acquiring Israel-based Taro Pharmaceuticals. "If we are able to get all the shares of Taro...
MP Labs accepts exit price for Matrix shares
MP Laboratories (Mauritius) has issued a public notice to the shareholders of Matrix Laboratories that it has accepted the price of Rs 211 an offer share (‘exit price’) established by the reverse book...
Novartis hikes offer price to Rs 450 a share
Swiss drugmaker Novartis has increased its offer price to acquire an additional 39 per cent in Novartis India Ltd, from the initially proposed Rs 351 to Rs 450 a share. The 28 per cent hike in offer price was to...
Taro acquisition may cost Sun Pharma Rs 1,000 crore
Indian drug firm Sun Pharma may have to shell out up to Rs 1,000 crore this fiscal for acquiring Israel-based Taro Pharmaceuticals. "If we are able to get all the shares of Taro Pharmaceuticals, including promoters...
Novartis may revise open offer price
Likely to increase buy-back offer from Rs 351 to Rs 425-450. Switzerland-based, Novartis AG, the parent company of Novartis India, is likely to revise its open offer price to buy back an additional stake of up to 39 per...
Parenteral Drugs – Updates on Scheme of Amalgamation
Parenteral Drugs India Ltd has informed BSE that by an order made on April 23, 2009, the Hon’ble High Court of Judicature at Bombay has directed that a meeting of the Equity Shareholders of the Company will be...
